文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo.

作者信息

Sato Takumi, Kakei Yasumasa, Hasegawa Takumi, Kashin Masahiko, Teraoka Shun, Yamaguchi Akinobu, Sasaki Ryohei, Akashi Masaya

机构信息

Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

Laboratory of Advanced Science and Technology for Industry, University of Hyogo, Kamigori 678-1205, Japan.

出版信息

Cancers (Basel). 2023 Dec 3;15(23):5697. doi: 10.3390/cancers15235697.

DOI:10.3390/cancers15235697
PMID:38067400
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10705767/
Abstract

INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) treatment includes surgery, radiotherapy, and immunotherapy with the aim of eradicating cancer cells without affecting normal tissues. HNSCC expresses epidermal growth factor receptor (EGFR) and cetuximab, an IgG1 monoclonal antibody targeting epidermal growth factor receptor, has been approved for the treatment of HNSCC. However, cetuximab has low reactivity and induces serious side effects. Gold nanoparticles (AuNPs) were reported to enhance the local antitumor effects of radiotherapy without damaging normal cells. METHODS AND RESULTS: This study investigated the in vitro effects of single and combination therapy with AuNPs (1.0 nM), cetuximab (30 nM), and radiotherapy (4 Gy) on a human HNSCC cell line, HSC-3. Combination treatment of AuNPs + cetuximab + radiotherapy markedly reduced HSC-3 numbers and proliferation and enhanced apoptosis compared with single and double combination treatments. Furthermore, the in vivo combination treatment (AuNPs + cetuximab + radiotherapy) of a xenograft model of HSC-3 cells transplanted into nude mice (BALB/cAJcl-nu/nu) reduced the tumor volume compared with the controls. Scanning electron microscopy demonstrated the presence of AuNPs in tumor tissues and toxicity analysis indicated that AuNPs had no toxic effect on normal tissues. CONCLUSIONS: This study showed that AuNPs alone do not have a tumor-suppressing effect, but they sensitize tumors to radiotherapy and bind to cetuximab, leading to enhanced antitumor effects.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/a0304c5ee991/cancers-15-05697-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/335d70af49b6/cancers-15-05697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/252d0f8fbb41/cancers-15-05697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/ab609b3f4a1b/cancers-15-05697-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/04139468a99d/cancers-15-05697-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/abb6c6ce3182/cancers-15-05697-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/4acf19f78015/cancers-15-05697-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/a0304c5ee991/cancers-15-05697-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/335d70af49b6/cancers-15-05697-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/252d0f8fbb41/cancers-15-05697-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/ab609b3f4a1b/cancers-15-05697-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/04139468a99d/cancers-15-05697-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/abb6c6ce3182/cancers-15-05697-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/4acf19f78015/cancers-15-05697-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ecb/10705767/a0304c5ee991/cancers-15-05697-g007.jpg

相似文献

[1]
Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo.

Cancers (Basel). 2023-12-3

[2]
Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells.

Biomed Res Int. 2020

[3]
EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair.

Radiat Res. 2013-9-23

[4]
Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.

Sci Rep. 2014-12-15

[5]
Gold nanoparticles enhance X-ray irradiation-induced apoptosis in head and neck squamous cell carcinoma .

Biomed Rep. 2018-11

[6]
Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.

Head Neck. 2017-1

[7]
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.

Mol Cancer Ther. 2014-7

[8]
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

J Immunother Cancer. 2019-3-19

[9]
Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.

J Oral Pathol Med. 2017-1-28

[10]
Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.

J Nucl Med. 2014-10

引用本文的文献

[1]
The Emerging Role of Nanoparticles Combined with Either Radiotherapy or Hyperthermia in Head and Neck Cancer: A Current Review.

Cancers (Basel). 2025-3-6

[2]
Revolutionizing radiotherapy: gold nanoparticles with polyphenol coating as novel enhancers in breast cancer cells-an in vitro study.

Discov Nano. 2025-1-15

[3]
Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.

Front Immunol. 2024-11-29

[4]
Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity.

Pharmaceutics. 2024-5-7

本文引用的文献

[1]
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure.

Front Oncol. 2023-9-13

[2]
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.

Front Oncol. 2023-8-1

[3]
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.

Int J Clin Oncol. 2022-12

[4]
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

J Clin Oncol. 2023-2-1

[5]
Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance.

Nat Commun. 2022-7-30

[6]
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Oral Oncol. 2022-5

[7]
Effect of National Oral Health Screening Program on the Risk of Head and Neck Cancer: A Korean National Population-Based Study.

Cancer Res Treat. 2022-7

[8]
Localized surface plasmon resonance inflection points for improved detection of chemisorption of 1-alkanethiols under total internal reflection scattering microscopy.

Sci Rep. 2021-6-18

[9]
Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.

Molecules. 2021-1-22

[10]
Therapeutic enhancement of radiation and immunomodulation by gold nanoparticles in triple negative breast cancer.

Cancer Biol Ther. 2021-2-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索